Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Phase 1 Not yet recruiting

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT07332975 2026-01-12

ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC

Not yet recruiting

77 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07321015 2026-01-06

Fzp-MA-TNBC

Phase 2 Not yet recruiting

72 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07299409 2025-12-23

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

Phase 2 Not yet recruiting

24 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Phase 2 Not yet recruiting

29 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05128734 2025-12-15

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

Phase 2 Not yet recruiting

40 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07271992 2025-12-09

TREND-02

Phase 2 Not yet recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07256964 2025-12-02

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

Phase 2 Not yet recruiting

216 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07244874 2025-11-24

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

Phase 2 Not yet recruiting

41 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07246759 2025-11-24

NEUTROFLOW

Not yet recruiting

600 enrolled

BreastDermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Triple Negative Breast Neoplasms

NCT07187674 2025-09-23

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Phase NA Not yet recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07178730 2025-09-17

ADAPT-TN-IV

Phase 3 Not yet recruiting

765 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07080619 2025-09-11

SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

Phase 2 Not yet recruiting

120 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05806385 2025-09-09

LOGIC

Phase 1/2 Not yet recruiting

36 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07161791 2025-09-09

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Phase 1/2 Not yet recruiting

12 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Phase 2 Not yet recruiting

150 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07153965 2025-09-04

Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

Phase 2 Not yet recruiting

47 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07151586 2025-09-03

ALTER

Phase 2 Not yet recruiting

260 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07015853 2025-08-27

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

Phase 2 Not yet recruiting

34 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07139470 2025-08-24

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Phase 1/2 Not yet recruiting

59 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

FERTILE

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC

RESTORE

QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.

AIDOBE

Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.

PLANET

EINSTEIN-TNBC

Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

BERLIN

EPPIL

P-RAD(+)TN-DCT

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

DUNP19

A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

RECLAIM

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

NoCUT-BC

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

POLARIS

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

FACT-TN

ADJUNCT

WISH-OMICHIR

OP-NEU-101

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC

Fzp-MA-TNBC

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

TREND-02

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

NEUTROFLOW

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

ADAPT-TN-IV

SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

LOGIC

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

ALTER

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer